Evidence Trace, complete trial record

In plain terms

In plain terms: Hesperidin shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.

Hesperidin

C Limited: small, mixed or unreplicated trials

Category Supplements

Evidence Meta-analyses of randomized trials + RCTs

Reviewed July 2026

PMIDs 30991044 · 27797708 · 39279783 · 41883255 · 42434414 · 42605853

The endpoint this grade is based on: Surrogate biomarker endpoint, C-reactive protein, where a 2019 meta-analysis was null and three later meta-analyses (2024 to 2026) each report a modest pooled reduction graded moderate certainty; the adhesion marker VCAM-1, where the pooled effect rests on three small trials and is graded very low certainty. One 2026 trial at a dietary dose found no vascular benefit. The trials mix purified hesperidin and a hesperidin 2S preparation at different doses in overweight adults, metabolic syndrome and after myocardial infarction, so the letter does not attach to one studied form.

The evidence as the record states it

Evidence record

PMID 30991044 PMID 27797708 PMID 39279783 PMID 41883255 PMID 42434414 PMID 42605853

Lorzadeh et al. (Chem Biol Interact, 2019; PMID 30991044): meta-analysis of 6 randomized trials, 296 participants; VCAM-1 lower, pooled from only 3 trials at P = 0.041; CRP, IL-6, ICAM-1 and E-selectin not changed overall. Salden et al. (Am J Clin Nutr, 2016; PMID 27797708): the primary trial behind the VCAM-1 pool, 68 overweight adults, hesperidin 2S 450 mg/day for 6 weeks; flow-mediated dilation did not change, VCAM-1, ICAM-1 and blood pressure showed trends only, and the significant VCAM-1 and postprandial findings came from an exploratory subgroup with baseline FMD of 3 percent or more that the authors say was not adjusted for multiplicity; funding not stated in the indexed record. Later syntheses: Huang et al. (Curr Dev Nutr, 2024; PMID 39279783): 12 trials, 589 participants, CRP 0.56 mg/L lower, with LDL, total cholesterol, fasting glucose, ICAM-1 and VCAM-1 also lower. Ouyang et al. (Br J Nutr, 2026; PMID 41883255): 10 trials, 532 participants, CRP and TNF-alpha lower, IL-6 not. Zhu et al. (Front Nutr, 2026; PMID 42434414): 16 trials, 845 overweight or obese participants; CRP 0.43 mg/L lower at moderate certainty, TNF-alpha and VCAM-1 lower at very low certainty, IL-6 and ICAM-1 not changed. Against: Gilcher et al. (Food Funct, 2026; PMID 42605853): randomized three-period crossover, 37 overweight men, hesperidin 210 mg/day for 6 weeks against orange juice and control; no effect on fasting or postprandial flow-mediated dilation or any vascular or metabolic parameter. Grade C: pooled surrogate effects of modest size across mixed preparations and populations, with the vascular trials null.

PMID 30991044 PMID 27797708 PMID 39279783 PMID 41883255 PMID 42434414 PMID 42605853

Why Grade C and not Grade B

Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.

What would move this grade

A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.

How to track whether this is working Systolic blood pressure and arterial stiffness (PWV if available) at baseline and 8 weeks for cardiovascular applications. CRP and IL-6 at baseline and 8 weeks. Hesperidin bioavailability depends on gut microbiome conversion to hesperetin: individuals with lower microbial diversity may have reduced responses.